The FDA maintains a category system for bulk drug substances used in compounding. This system helps determine what pharmacies can legally compound. Think of it as a traffic light system for pharmaceutical ingredients.
Category 1 includes substances the FDA considers safe for compounding. These have passed review and can be used when other conditions are met. Category 2 contains substances under evaluation. Category 3 covers those with insufficient data.
According to FDA regulations, materials in Category 1 may be used as bulk drug substances, provided all other legal and regulatory conditions are met. However, substances in Category 2 and Category 3 may not be compounded.
503A Compounding Pharmacies
These are traditional state-licensed pharmacies. They compound medications based on specific patient prescriptions. Your local compounding pharmacy likely operates under 503A regulations.
FDA guidelines state that 503A pharmacies must comply with USP standards and state regulations. They can compound substances that are FDA-approved active ingredients, have USP monographs, or appear on the Category 1 list.
Key characteristics of 503A compounding:
Patient-specific prescriptions required
State board of pharmacy oversight
Limited interstate commerce
Smaller batch sizes
More flexibility in formulations
503B Outsourcing Facilities
These are larger compounding operations. They can produce medications without patient-specific prescriptions. However, they face stricter regulations.
503B facilities must:
Only use Category 1 substances or drugs in shortage
Validate every process according to Current Good Manufacturing Practices (CGMP)
Submit multiple batches for testing and stability
Register with the FDA
Meet federal oversight requirements
No, not legally. After removal from Category 2 and FDA’s recommendation against 503A inclusion, compounding pharmacies cannot compound these substances. The regulatory review continues, but current status prohibits compounding.
Compounded peptides are made by pharmacies for patient use under prescription. Research-grade peptides are manufactured for scientific research only and cannot be used for human consumption. They serve different purposes under different regulations.
Specific reasons weren’t publicly disclosed. Nominators may withdraw substances for various reasons, including regulatory strategy, business decisions, or concerns about meeting FDA requirements. The withdrawals triggered the September 2024 removals.
No FDA-approved versions of ipamorelin or CJC-1295 currently exist for commercial use. Some growth hormone secretagogues have approval for specific indications, but these particular peptides remain unapproved for therapeutic use.
The FDA hasn’t announced a specific timeline. Regulatory reviews can take months to years depending on complexity, data requirements, and agency priorities. Stakeholders await further guidance.
Without legal compounding options and no FDA-approved products, prescribing these peptides for therapeutic use is extremely limited. Doctors must explore alternative treatments that are legally available.
FDA-approved growth hormone products exist for specific medical conditions. Other peptides with different regulatory status might serve some research purposes. Healthcare providers can discuss legal options based on individual circumstances.
Research institutions can still obtain research-grade peptides from licensed suppliers for legitimate scientific studies. The compounding restrictions don’t prohibit properly conducted research with appropriate materials and oversight.
It’s possible but uncertain. The FDA could approve them for 503A compounding after completing its review. However, based on current recommendations, the agency appears cautious about allowing compounding without additional data or safeguards.
Monitor FDA announcements, subscribe to regulatory newsletters, and follow industry publications. Professional organizations for compounding pharmacists also provide updates. Regulatory landscapes change, so staying informed is important.
